Producer
Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc. (Bridgewater NJ; NYSE: AMRX; ~$2.5B revenue) is a generic pharmaceutical company with injectable opioid manufacturing capabilities producing morphine sulfate injection, fentanyl citrate injection, and hydromorphone HCl injection. Amneal's injectable manufacturing serves the US hospital generics market. Amneal competes with Fresenius Kabi, Hikma, and Pfizer/Hospira on injectable opioid contracts through hospital group purchasing organizations (GPOs). As a smaller injectable manufacturer relative to Fresenius Kabi and Hikma, Amneal's injectable opioid vial lines represent a secondary US source rather than a primary volume supplier.
1
Inputs supplied
1
Goods downstream
0
Facilities
0
Stories
What they make
1 input Amneal Pharmaceuticals Inc. supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Amneal Pharmaceuticals Inc. makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Generic Injectables (incl. Controlled)
45%Specialty Pharmaceuticals
28%Complex Generics
17%Biosimilars
10%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2024
Amneal manufactures generic injectable opioids (morphine, fentanyl, hydromorphone — controlled substance supply chain) AND is building a biosimilar portfolio including an adalimumab biosimilar (Hadlima — for rheumatoid arthritis, Crohn's disease) that competes with Humira, the world's best-selling drug. The same generic pharmaceutical company contributing to the controlled substance supply chain for hospital pain management is simultaneously a new entrant to the biologic/immunology drug supply chain through biosimilars. Hospital formulary committees and specialty pharmacy benefit managers who separately manage controlled substance policies and biologic treatment protocols are both interacting with Amneal without recognizing the shared upstream manufacturer.
Amneal Pharmaceuticals ↗Origin2023
Amneal Pharmaceuticals was founded in 2002 by brothers Chirag Patel and Chintu Patel in Bridgewater, New Jersey — Indian-American entrepreneurs who grew up in a pharmaceutical family. The Patel brothers built Amneal into one of the fastest-growing US generic pharmaceutical companies of the 2000s by focusing on complex generic formulations and injectable products that had higher regulatory barriers than standard oral tablet generics. In 2018, Amneal merged with Impax Laboratories (adding specialty CNS products) and listed on the NYSE, becoming one of the top-5 US generic pharmaceutical companies by revenue.
Amneal Pharmaceuticals ↗